Research programme: NRAS protein inhibitors - FogPharma
Alternative Names: NRAS (ON) - FogPharmaLatest Information Update: 30 Dec 2022
At a glance
- Originator FogPharma
- Class Antineoplastics; Peptides
- Mechanism of Action NRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 13 Dec 2022 Early research in Cancer in USA (unspecified route) (FogPharma pipeline, December 2022)
- 31 Dec 2017 Harvard university licenses Helicon™ peptides technology to FogPharma prior to December 2017 (FogPharma website, March 2021)